Artiva Biotherapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
ARTV$4.22+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| YEAR ENDED DECEMBER 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue: | ||
| Collaboration revenue | $— | $32,923 |
| License and development support revenue (including related party amounts of $251 and $569, respectively) | 251 | 569 |
| Total revenue | 251 | 33,492 |
| Operating expenses: | ||
| Research and development (including related party amounts of $3,168 and $3,832, respectively) | 50,328 | 50,251 |
| General and administrative | 17,205 | 13,912 |
| Total operating expenses | 67,533 | 64,163 |
| Loss from operations | (67,282) | (30,671) |
| Other income, net: | ||
| Interest income | 5,349 | 2,535 |
| Change in fair value of SAFEs (including related party amounts of $2,911 and $573, respectively) | (3,597) | (707) |
| Other income, net | 157 | 195 |
| Total other income, net | 1,909 | 2,023 |
| Loss before provision for income taxes | (65,373) | (28,648) |
| Provision for income taxes | — | (72) |
| Net loss | $(65,373) | $(28,720) |
| Net loss per share, basic and diluted | $(5.81) | $(35.78) |
| Weighted-average common shares outstanding, basic and diluted | 11,258,851 | 802,747 |
| Comprehensive loss: | ||
| Net loss | $(65,373) | $(28,720) |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on investments | (437) | 308 |
| Comprehensive loss | $(65,810) | $(28,412) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.